Literature DB >> 30529108

Incidence, risk factors and outcome of multi-drug resistant Acinetobacter baumannii nosocomial infections during an outbreak in a burn unit.

Anne-Lise Munier1, Lucie Biard2, Matthieu Legrand3, Clotilde Rousseau4, Matthieu Lafaurie5, Jean-Luc Donay4, Rémi Flicoteaux2, Alexandre Mebazaa3, Maurice Mimoun6, Jean-Michel Molina5.   

Abstract

BACKGROUND: Multidrug-Resistant Acinetobacter baumannii (MR-AB) can cause outbreaks in burn units. We aimed to study the incidence, risk factors and outcome of MR-AB infections in a burn unit (BU).
METHODS: A prospective study was conducted from April to November, 2014 during an outbreak in a BU in Paris. Weekly surveillance cultures were performed to determine MR-AB colonization. MR-AB nosocomial infections, discharge or death without MR-AB infection were considered as competing events. To identify risk factors for MR-AB infection, baseline characteristics and time-dependent variables were investigated in univariate analyses using Cox models.
RESULTS: Eighty-six patients admissions were analyzed during the study period. Among them, 15 (17%) acquired MR-AB nosocomial infection. Median time to infection was 22days (interquartile range: 10-26 days). Cumulative incidence of MR-AB infections was 15% at 28days (95% CI=8-24). Risk factors for MR-AB infection in univariate analysis were SAPS II (Hazard Ratio (HR):1.08; 95% CI:1.05-1.12; P<0.0001) and ABSI (Abbreviated Burn Severity Index) scores (HR:1.32; 95% CI:1.12-1.56; P=0.001), MR-AB colonization (HR:10.2; 95%CI:2.05-50.3; P=0.004), invasive procedures (ventilation, arterial and/or venous catheter) (P=0.0001) and ≥2 skin grafts (HR:10.2; 95% CI:1.76-59.6; P=0.010). MR-AB infection was associated with an increased risk of death (HR: 7.11; 95%CI: 1.52-33.2; P=0.013) and longer hospital stay with a median estimated increase of 10days (IQR: 6; 14).
CONCLUSIONS: Incidence of MR-AB nosocomial infection was high during this outbreak, and was associated with prolonged hospitalization and increased risk of death. High patient severity scores, prior MR-AB colonization, invasive procedures and repeated skin grafts were associated with an increased risk of nosocomial infection.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Acinetobacter baumannii; Antibiotic resistance; Burns; Infection; Risk factors

Mesh:

Year:  2018        PMID: 30529108     DOI: 10.1016/j.ijid.2018.11.371

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  16 in total

Review 1.  Management and prevention of drug resistant infections in burn patients.

Authors:  Roohi Vinaik; Dalia Barayan; Shahriar Shahrokhi; Marc G Jeschke
Journal:  Expert Rev Anti Infect Ther       Date:  2019-08-04       Impact factor: 5.091

2.  Prediction of the Risk of Hospital Deaths in Patients with Hospital-Acquired Pneumonia Caused by Multidrug-Resistant Acinetobacter baumannii Infection: A Multi-Center Study.

Authors:  Hongmei Shu; Lijuan Li; Yimin Wang; Yiqun Guo; Chunlei Wang; Chunxia Yang; Li Gu; Bin Cao
Journal:  Infect Drug Resist       Date:  2020-11-19       Impact factor: 4.003

3.  Evaluation the reactivity of a peptide-based monoclonal antibody derived from OmpA with drug resistant pulsotypes of Acinetobacter baumannii as a potential therapeutic approach.

Authors:  Omid Yeganeh; Mahdi Shabani; Parviz Pakzad; Nariman Mosaffa; Ali Hashemi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-06-30       Impact factor: 6.781

4.  Control of Acinetobacter baumannii outbreak in the neonatal intensive care unit in Latvia: whole-genome sequencing powered investigation and closure of the ward.

Authors:  A Gramatniece; I Silamikelis; Ie Zahare; V Urtans; Ir Zahare; E Dimina; M Saule; A Balode; I Radovica-Spalvina; J Klovins; D Fridmanis; U Dumpis
Journal:  Antimicrob Resist Infect Control       Date:  2019-05-22       Impact factor: 4.887

Review 5.  Host Innate Immune Responses to Acinetobacter baumannii Infection.

Authors:  Wangxue Chen
Journal:  Front Cell Infect Microbiol       Date:  2020-09-14       Impact factor: 5.293

Review 6.  Interplay between ESKAPE Pathogens and Immunity in Skin Infections: An Overview of the Major Determinants of Virulence and Antibiotic Resistance.

Authors:  Gustavo Henrique Rodrigues Vale de Macedo; Gabrielle Damasceno Evangelista Costa; Elane Rodrigues Oliveira; Glauciane Viera Damasceno; Juliana Silva Pereira Mendonça; Lucas Dos Santos Silva; Vitor Lopes Chagas; José Manuel Noguera Bazán; Amanda Silva Dos Santos Aliança; Rita de Cássia Mendonça de Miranda; Adrielle Zagmignan; Andrea de Souza Monteiro; Luís Cláudio Nascimento da Silva
Journal:  Pathogens       Date:  2021-02-02

7.  Low-temperature laminar flow ward for the treatment of multidrug resistance Acinetobacter baumannii pneumonia.

Authors:  Zhitao Gong; Jin Li; Hongliang Luo; Daqiang Zhan; Xuanhui Liu; Chuang Gao; Jinhao Huang; Yu Qian; Yiming Song; Wei Quan; Shuo An; Ye Tian; Zhidong Hu; Jian Sun; Hengjie Yuan; Rongcai Jiang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-02       Impact factor: 3.267

8.  Epidemiological situation, laboratory capacity and preparedness for carbapenem-resistant Acinetobacter baumannii in Europe, 2019.

Authors:  Felix Lötsch; Barbara Albiger; Dominique L Monnet; Marc J Struelens; Harald Seifert; Anke Kohlenberg
Journal:  Euro Surveill       Date:  2020-11

9.  Antibiotic resistance assessment of Acinetobacter baumannii isolates from Tehran hospitals due to the presence of efflux pumps encoding genes (adeA and adeS genes) by molecular method.

Authors:  Batool Basatian-Tashkan; Mohammad Niakan; Mansoor Khaledi; Hamed Afkhami; Fatemeh Sameni; Shahriar Bakhti; Reza Mirnejad
Journal:  BMC Res Notes       Date:  2020-11-19

10.  Circumventing colistin resistance by combining colistin and antimicrobial peptides to kill colistin-resistant and multidrug-resistant Gram-negative bacteria.

Authors:  Kaitlin S Witherell; Jason Price; Ashok D Bandaranayake; James Olson; Douglas R Call
Journal:  J Glob Antimicrob Resist       Date:  2020-06-05       Impact factor: 4.035

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.